Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients

Fig. 2

Flow chart of the two-period retrospective case–control study. In total 295 patients received iEPO in adult ICUs between August 2015 and December 2019. After excluding 131 patients, 164 patients were included for analysis. 80 patients received iEPO via low concentration delivery strategy from August 2015 to December 2017. With this strategy, three different concentrations of iEPO (750 mcg/50 mL, 375 mcg/50 mL, and 125 mcg/50 mL) and different pump rate were used, based on the prescribed dose (screenshot of the syringe pump was shown on the bottom left). 84 patients received iEPO via high concentration delivery strategy from January 2018 to December 2019. With this strategy, only one concentration (1500 mcg/50 mL) was used, and pump rate was adjusted to deliver different prescribed dose (screenshot of the syringe pump was shown on the bottom right). iEPO inhaled epoprostenol, OR operating room, ECMO extracorporeal membrane oxygenation, HHHFNC high-flow high humidity nasal cannula, NIV noninvasive ventilation, IV EPO intravenous epoprostenol, ICU intensive care unit, iNO inhaled nitric oxide

Back to article page